Metal Containing, E.g., Chromoproteins, Ferritin, Ferredoxins, Etc. Patents (Class 530/400)
  • Patent number: 9393327
    Abstract: Methods and compositions are provided for labeling proteins with radiohalogen-label reagents. Radiohalogen-labeled proteins may be used for imaging studies, as therapeutics and in diagnostic tests. The [125I] HIP-DOTA label reagent 6 is prepared by an efficient and convenient process.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: July 19, 2016
    Assignee: GENENTECH, INC.
    Inventors: Charles Andrew Boswell, Leslie A Khawli, Jan Marik, Simon Williams
  • Patent number: 9314479
    Abstract: The invention relates to methods of inhibiting biofilm formation or reducing biofilms in a subject or on a device or surface by administering a charged compound such as a polyamino acid to a subject, device or surface. The invention also relates to compositions for inhibiting biofilm formation or reducing biofilms.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: April 19, 2016
    Assignee: National Jewish Health
    Inventors: Jerry A. Nick, Quinn M. Parks
  • Patent number: 9187519
    Abstract: Reactive nanocomposites comprising a metal nanoparticle functionalized with one or more layers of self-assembled protein cages and methods of making the same. The reactive nanocomposites according to the present invention demonstrate improved reaction kinetics and enhanced exothermic behavior.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: November 17, 2015
    Assignee: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE
    Inventors: Joseph M Slocik, Christopher A Krouse, Rajesh R Naik
  • Patent number: 9090711
    Abstract: A method of selectively arraying ferritin and inorganic particles on a silicon oxide substrate having a chromium, niobium or tungsten portion. An aspect of the method includes steps of: preparing a solution which contains ferritin modified at an N-terminal part of a subunit with a peptide set out in SEQ ID NO: 1, and a nonionic surfactant; and a binding step of bringing the solution in contact with the silicon oxide substrate to selectively array peptide-modified ferritin to the chromium, niobium or, tungsten portion. Another aspect of the method includes selectively arraying ferritin modified with the peptide set out in SEQ ID NO: 1, and the inorganic particles contained in ferritin at the chromium, niobium, or tungsten portion by removing the solution.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: July 28, 2015
    Assignee: PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD.
    Inventor: Nozomu Matsukawa
  • Publication number: 20150125423
    Abstract: The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens.
    Type: Application
    Filed: January 12, 2015
    Publication date: May 7, 2015
    Inventors: Jennifer Mitcham, Matthew Moyle
  • Publication number: 20150104818
    Abstract: The present invention comprises novel conjugates and immunogens derived from gemcitabine and unique antibodies generated by using gemcitabine linked immunogens, which conjugates immunogens and antibodies, are useful in immunoassays for the quantification and monitoring of gemcitabine in biological fluids.
    Type: Application
    Filed: December 19, 2014
    Publication date: April 16, 2015
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Howard Sard, Christopher Spedaliere
  • Patent number: 8968687
    Abstract: A method for recycling metals is provided by using extracellular proteins excreted by a specific thermophilic bacteria strain, Tepidimonas fonticaldi sp. nov., in which the extracellular proteins show excellent metal-ion binding ability, being useful in recycling rare earth metal ions and precious metal ions from geothermal fluids, boiler solutions, industrial wastewater or hard water.
    Type: Grant
    Filed: December 30, 2013
    Date of Patent: March 3, 2015
    Assignee: Industrial Technology Research Institute
    Inventors: Yin-Lung Han, Tai-Rong Guo, Jo-Shu Chang, Yung-Chong Lou, Wan-Ju Yu
  • Publication number: 20150038672
    Abstract: Targeting agents are derived from coupling together formed imaging amino acids or formed multi-modal, multi-chelating metal, multi-dye imaging agents, or combinations of these, that may be conjugated directly, or activated, or attached to linkers to which targeting groups, such as peptides, proteins, antibodies, aptamers, or small molecule inhibitors, may be conjugated in the final steps of the synthesis to form a wide variety of TMIAs.
    Type: Application
    Filed: August 1, 2014
    Publication date: February 5, 2015
    Applicant: Rochester Institute of Technology
    Inventors: Hans F. Schmitthenner, Stephanie Beach, Chelsea Weidman, Taylor Barrett
  • Patent number: 8945512
    Abstract: Disclosed are CEST paramagnetic agents comprising a substrate (SH) containing mobile protons bonded to a paramagnetic chelate (SR) containing a metal selected from iron (11) (high-spin configuration), iron (111), cobalt (11), rhodium (11), copper (11), nickel (11), cerium (111), praseodymium (111), neodymium (111), dysprosium (111), erbium (111), terbium (111), holmium (111), thulium (III), ytterbium (III) and europium (111).
    Type: Grant
    Filed: April 6, 2004
    Date of Patent: February 3, 2015
    Assignee: Bracco Imaging SpA
    Inventors: Silvio Aime, Enzo Terreno, Daniela Delli Castelli, Giovanni Battista Giovenzana
  • Publication number: 20150024456
    Abstract: Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays.
    Type: Application
    Filed: July 30, 2014
    Publication date: January 22, 2015
    Inventors: Johnny Jose Valdez, Byung Sook Moon, Michael Kevin Helms, Alejandro A. Orozco
  • Patent number: 8906633
    Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: December 9, 2014
    Assignee: Randox Laboratories Limited
    Inventors: Elouard Benchikh, Stephen Peter Fitzgerald, Paul John Innocenzi, Philip Andrew Lowry, Ivan Robert McConnell
  • Publication number: 20140329718
    Abstract: The invention relates to a genetically encoded fluorescent sensor for nicotinamide adenine dinucleotide, as well as methods of preparation and uses thereof. In one aspect, this invention relates to a sensor for detecting nicotinamide adenine dinucleotide, particularly, a recombinant fluorescent fusion protein sensor for detecting nicotinamide adenine dinucleotide. In one specific aspect, this invention relates to a recombinant fluorescent fusion protein sensor for detecting reduced nicotinamide adenine dinucleotide (NADH); in another specific aspect, this invention relates to a recombinant fluorescent fusion protein sensor for detecting oxidized nicotinamide adenine dinucleotide (NAD+); in yet another aspect, the invention relates to a recombinant fluorescent fusion protein sensor for detecting the ratio of reduced to oxidized nicotinamide adenine dinucleotide.
    Type: Application
    Filed: September 26, 2012
    Publication date: November 6, 2014
    Applicant: East China University of Science and Technology
    Inventors: Yi Yang, Jing Jin, Yuzheng Zhao, Qingxun Hu
  • Publication number: 20140322306
    Abstract: The invention provides a molecule that inhibits or prevents an interaction between a Src family kinase and an androgen or estradiol receptor, for use in preventing or treating a non-cancerous condition in which an activity of AR and/or ER is a contributory factor in a subject, or for use in preventing or treating a cancerous condition in which an activity of AR and/or ER is a contributory factor in a subject who wishes to preserve fertility, or for use in preventing or treating a gynaecological condition in which an activity of AR and/or ER is a contributory factor in a subject.
    Type: Application
    Filed: November 1, 2012
    Publication date: October 30, 2014
    Inventors: Mark Eccleston, Satu Vainikka, George Steven Morris
  • Publication number: 20140302554
    Abstract: A compound may generally comprise the formula: wherein R1 is independently selected from C2-C10 alkyl or substituted alkyl, R2 is independently selected from the group consisting of —H and C1-C6 alkyl or substituted alkyl, X is selected from the group consisting of —NH— and —O—, Y is a carbohydrate, and m is an integer from 1 to 8. The compound may comprise a non-ionic acid labile surfactant. The compound may be used to facilitate solubilization of proteins and other molecules in an aqueous environment.
    Type: Application
    Filed: June 23, 2014
    Publication date: October 9, 2014
    Inventors: Matthew Jacob Powell, Trust T. Razunguzwa, Miaosheng Li
  • Publication number: 20140302079
    Abstract: Novel vaccines are provided that elicit broadly neutralizing anti-influenza antibodies. Some vaccines comprise nanoparticles that display hemagglutinin trimers from influenza virus on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of ferritin joined to at least a portion of an influenza hemagglutinin protein. Some portions comprise the ectodomain while some portions are limited to the stem region. The fusion proteins self-assemble to form the hemagglutinin-displaying nanoparticles. Some vaccines comprise only the stem region of an influenza hemagglutinin protein joined to a trimerization domain. Such vaccines can be used to vaccinate an individual against infection by heterologous influenza viruses and influenza virus that are antigenically divergent from the virus from which the nanoparticle hemagglutinin protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.
    Type: Application
    Filed: September 24, 2012
    Publication date: October 9, 2014
    Inventors: Gary J. Nabel, Masaro Kanekiyo, Chih-Jen Wei, Patrick M. Mctamney, Hadi M. Yassine, Jeffrey C. Boyington
  • Publication number: 20140302527
    Abstract: This invention relates to a target-specific probe containing a ferritin fusion protein and a targeting agent, a target-specific imaging probe containing a labeling agent coupled to the target-specific probe, and a detection method or detection kit of a biomarker using these probes.
    Type: Application
    Filed: May 22, 2013
    Publication date: October 9, 2014
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Kwan-Hyi LEE, Jong-Hoon Choi, Mintai Peter Hwang, Yu-Chan Kim, Jong-Wook Lee, Hyun-Kwang Seok
  • Publication number: 20140295410
    Abstract: Disclosed are a conjugate of a metal nanoparticle including a magnetic core and at least one light emitting material linked to the metal nanoparticle through a linker, wherein the linker has an affinity for a biological material and has changed structure after contacting a biological material, a biosensor including the conjugate, and a method of measuring a concentration of specific biological material in a biological sample using the conjugate or the biosensor.
    Type: Application
    Filed: February 19, 2014
    Publication date: October 2, 2014
    Inventors: Shin Ae JUN, Dae ha Seo, Eun Joo JANG, Young-Wook Jun
  • Publication number: 20140271467
    Abstract: Embodiments of the present disclosure provide for labeled probes such as a 64Cu-FN3 probe (FN3 refers to fibronectin type 3 domain); methods of making labeled probes; pharmaceutical compositions including labeled probes; methods of using labeled probes; methods of diagnosing, localizing, monitoring, and/or assessing non-Hodgkin's lymphoma, cancers, tumors, precancerous cells, and related biological events using labeled probes; kits for diagnosing, localizing, monitoring, and/or assessing non-Hodgkin's lymphoma, cancers, tumors, precancerous cells, and related biological events; and the like.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 18, 2014
    Inventors: Benjamin Hackel, Arutselvan Natarajan, Sanjiv S. Gambhir
  • Publication number: 20140256918
    Abstract: Disclosed herein are methods for immobilizing membrane proteins or membrane protein complexes on analytical surfaces, which in some aspects comprise: obtaining a membrane protein or membrane protein complex comprising a capture moiety; immobilizing the membrane protein or membrane protein complex on the analytical surface by means of the capture moiety; and stabilizing at least one of the secondary, tertiary, or quaternary structures of the immobilized membrane protein or membrane protein complex by crosslinking with a crosslinking reagent. Also disclosed are analytical surfaces, which in some aspects comprise: a membrane protein or membrane protein complex comprising a capture moiety, wherein the membrane protein or membrane protein complex is immobilized on the analytical surface by means of the capture moiety, and wherein at least one of the secondary, tertiary, or quaternary structures of the membrane protein or membrane protein complex is stabilized by crosslinking.
    Type: Application
    Filed: January 17, 2014
    Publication date: September 11, 2014
    Inventors: Ruiyin Chu, David James Reczek
  • Publication number: 20140255476
    Abstract: Compositions, devices, and methods for treating infections.
    Type: Application
    Filed: August 20, 2012
    Publication date: September 11, 2014
    Applicant: University of Washington through its Center for Commercialization
    Inventors: Rodney J.Y. Ho, Brenda Newman
  • Publication number: 20140255345
    Abstract: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.
    Type: Application
    Filed: October 16, 2013
    Publication date: September 11, 2014
    Applicant: Allozyne, Inc.
    Inventors: Kenneth H. Grabstein, David A. Tirrell
  • Patent number: 8828238
    Abstract: A novel thermophilic bacterium is provided, which has a 16S rDNA sequence as set forth in SEQ ID NO. 1. The thermophilic bacterium excretes extracellular proteins having excellent metal-ion binding ability, being useful in the treatment of boiler equipment, pipelines, geothermal wells or industrial wastewater or hard water.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: September 9, 2014
    Assignee: Industrial Technology Research Instiute
    Inventors: Yin-Lung Han, Tai-Rong Guo, Jo-Shu Chang, I-Ju Chou
  • Patent number: 8828542
    Abstract: Nanoparticles can include a core linked to a polymerizable moiety that can be polymerized, cross-linked or cured. The polymerizable nanoparticles can be included in a composition for a polymerization, cross-linking or curing reaction in an amount and disposition sufficient for inhibiting or preventing volume shrinkage during polymerization, cross-linking or curing reaction. Also, the nanoparticles can be included with monomers, dendrimers, oligomers or polymers in the compositions that can be reacted to form a polymerized, cross-linked or cured product.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: September 9, 2014
    Assignee: Korea University Research and Business Foundation
    Inventor: Dong Hoon Choi
  • Publication number: 20140248339
    Abstract: A multi-component nanochain for use in diagnostic and therapeutic applications includes at least three nanoparticles linked together to form the nanochain. At least one nanoparticle of the nanochain has an asymmetric surface chemistry defined by asymmetrically disposed first linkers and second linkers. The nanoparticles are linked to form the nanochain by linking first linkers and/or second linkers disposed on separate nanoparticles.
    Type: Application
    Filed: October 12, 2012
    Publication date: September 4, 2014
    Applicant: Case Western Reserve University
    Inventors: Efstathios Karathanasis, Pubudu M. Peiris, Mark Griswold
  • Publication number: 20140242723
    Abstract: Method of detecting Symmetrical dimethyl arginine (SDMA) in biological samples. SDMA analogs for generating anti-SDMA antibodies having little or no cross-reactivity with asymmetrical dimethyl arginine, arginine, and monomethylarginine. The analogs have a protected or free thiol (—SH) group or hydroxyl (—OH) group that allow them to be linked to a suitable conjugation target which can be, for example, a protein containing molecule of a label. The anti-SDMA antibodies can be used in diagnostic immunoassay for the diagnosis of SDMA associated disorders and/or diseases.
    Type: Application
    Filed: February 28, 2014
    Publication date: August 28, 2014
    Applicant: IDEXX Laboratories, Inc.
    Inventors: Murthy V.S.N. Yerramilli, Mahalakshmi Yerramilli, Michael Atkinson, Kwok Kam Yeung
  • Publication number: 20140234855
    Abstract: Chromophore compositions and methods of making and using the same are provided. Aspects of the chromophore compositions include a chromophore component having a chromophore, such as a fluorescent dye moiety, stably associated with a prosthetic group binding cavity of a metalloprotein. Also provided are methods of making, methods of use, systems and kits related to the subject fluorescent compositions.
    Type: Application
    Filed: February 10, 2014
    Publication date: August 21, 2014
    Inventors: Majid Mehrpouyan, Oleg Guryev, Marybeth Sharkey
  • Publication number: 20140234365
    Abstract: The present invention relates to novel 2-hydroxyhippuric acid analogs, and methods for their synthesis and use. Such analogs are designed to provide a protected or functional moiety such as a free thiol (—SH) group or a protected thiol group, thereby providing a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label.
    Type: Application
    Filed: September 27, 2012
    Publication date: August 21, 2014
    Applicant: ALERE SAN DIEGO, INC.
    Inventor: Mariusz Banaszczyk
  • Publication number: 20140227717
    Abstract: Methods, compositions and kits are disclosed directed at posaconazole fragments, immunogens, signal generating moieties, antibodies that bind posaconazole and immunoassays for detection of posaconazole.
    Type: Application
    Filed: February 10, 2014
    Publication date: August 14, 2014
    Inventors: Johnny Valdez, Soon J. Oh, Byung Sook Moon
  • Patent number: 8796417
    Abstract: It is to provide an inorganic thin film of titanium dioxide or the like which is controlled at the nanoscale and a three-dimensional structure of a functional material such as semiconductor nanoparticles.
    Type: Grant
    Filed: May 24, 2006
    Date of Patent: August 5, 2014
    Assignee: Japan Science and Technology Agency
    Inventors: Kiyotaka Shiba, Kenichi Sano
  • Publication number: 20140193316
    Abstract: A method for recycling metals is provided by using extracellular proteins excreted by a specific thermophilic bacteria strain, Tepidimonas fonticaldi sp. nov., in which the extracellular proteins show excellent metal-ion binding ability, being useful in recycling rare earth metal ions and precious metal ions from geothermal fluids, boiler solutions, industrial wastewater or hard water.
    Type: Application
    Filed: December 30, 2013
    Publication date: July 10, 2014
    Applicant: Industrial Technology Research Institute
    Inventors: Yin-Lung HAN, Tai-Rong GUO, Jo-Shu CHANG, Yung-Chong LOU, Wan-Ju YU
  • Publication number: 20140194602
    Abstract: A genetically modified cowpea mosaic virus (CPMV) protein capsid serves as a scaffold for metal nanoparticles, preferably gold nanospheres, of 15 nm to 35 nm, creating plasmonic nanoclusters. The self-assembled nanoclusters gave rise to a 10-fold surface-averaged enhancement of the local electromagnetic field. Other viral capsids or virus-like proteins may also serve as such scaffolds.
    Type: Application
    Filed: March 13, 2014
    Publication date: July 10, 2014
    Applicant: The Government of the United States of America, as represented by the Secretary of the Navy
    Inventors: Banahalli R. Ratna, Carissa M. Soto, Ronald W. Rendell, Jake Fontana, Jeffrey R. Deschamps
  • Publication number: 20140163206
    Abstract: The invention relates to compounds of Formula I, wherein R1, R2, and R3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from aripiprazole. The invention also relates to conjugates of an aripiprazole hapten and a protein.
    Type: Application
    Filed: August 20, 2013
    Publication date: June 12, 2014
    Applicants: Ortho-Clinical Diagnostics, Inc., JANSSEN PHARMACEUTICA NV
    Inventors: Ronghui LIN, Rhys SALTER, Thomas R. DeCORY, Eric HRYHORENKO, Bart REMMERIE, Banumathi SANKARAN
  • Publication number: 20140155585
    Abstract: The invention relates to compounds of Formula I, wherein R1 and R2 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from risperidone and paliperidone. The invention also relates to conjugates of a risperidone or paliperidone hapten and a protein.
    Type: Application
    Filed: August 20, 2013
    Publication date: June 5, 2014
    Applicants: Ortho-Clinical Diagnostics, Inc., Janssen Pharmaceutica NV
    Inventors: Pieter Rik HASPESLAGH, Maarten VLIEGEN, Eric HRYHORENKO, Thomas R. DeCORY, Banumathi SANKARAN
  • Patent number: 8735555
    Abstract: This invention pertains to the discovery of mutant phytochromes that when introduced into a plant alter the photomorphogenic properties of that plant. In certain embodiments transfection of plants by nucleic acid constructs expressing the mutant phytochromes produced plants having a phenotype characterized by light-independent activation. Thus, in certain embodiments, this invention provides a transgenic plant or plant cell comprising a mutant phytochrome where the mutant phytochrome is a light-stable phytochrome; and the transgenic plant shows decreased shade avoidance as compared to the same species or strain of plant lacking the mutant phytochrome. In various embodiments the mutant phytochrome comprises a mutation at the position corresponding to tyrosine residue 276 in an Arabidopsis phytochrome where the mutation is to a residue other than tyrosine.
    Type: Grant
    Filed: April 16, 2007
    Date of Patent: May 27, 2014
    Assignee: The Regents of the University of California
    Inventors: John Clark Lagarias, Yi-Shin Su
  • Patent number: 8710195
    Abstract: A fluorescent protein (bFP) having chemiluminescence activity is a complex composed of the apoprotein of a calcium-binding photoprotein, coelenteramid or an analog thereof, and calcium ions or divalent or trivalent ions that can be substituted for the calcium ions. In the complex, the ratio of the number of molecules of the apoprotein to that of the coelenteramid is 1:1 and the ratio of the number of molecules of the apoprotein to that of the divalent or trivalent ions is 1:1 to 1:4. The fluorescent protein is used as a marker because it catalyzes luminescence of coelenterazine and has fluorescence capability. Removal of calcium ions etc. from this fluorescent protein (bFP) having luminescence activity provides a novel fluorescent protein (gFP). Mixing this gFP with the coelenterazine provides a calcium-binding photoprotein, which emit light instantaneously, enabling use as a marker.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: April 29, 2014
    Assignee: JNC Corporation
    Inventor: Satoshi Inouye
  • Publication number: 20140093913
    Abstract: Methods and compositions for a genetic disease are provided.
    Type: Application
    Filed: August 29, 2013
    Publication date: April 3, 2014
    Inventors: Gregory J. Cost, Philip D. Gregory, Dmitry Guschin, Michael C. Holmes, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Andreas Reik, Fyodor Urnov, Lei Zhang
  • Publication number: 20140093934
    Abstract: In a process for producing organic substrate particles bonded to switchable ferromagnetic nanoparticles with a mean particle diameter in the range from 10 to 1000 nm, the ferromagnetic nanoparticles used are those nanoparticles which are nonferromagnetic at first, but become ferromagnetic when the temperature is lowered, these at first nonferromagnetic nanoparticles in dispersed form are bonded to the organic substance particles, and then the nanoparticles bonded to the substrate particles are made ferromagnetic as a result of the temperature being lowered.
    Type: Application
    Filed: December 6, 2013
    Publication date: April 3, 2014
    Applicant: BASF SE
    Inventor: Ekkehard BRUECK
  • Publication number: 20140072958
    Abstract: Novel vaccines are provided that elicit broadly neutralizing anti-influenza antibodies. Some vaccines comprise nanoparticles that display hemagglutinin trimers from influenza virus on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of ferritin joined to at least a portion of an influenza hemagglutinin protein. Some portions comprise the ectodomain while some portions are limited to the stem region. The fusion proteins self-assemble to form the hemagglutinin-displaying nanoparticles. Some vaccines comprise only the stem region of an influenza hemagglutinin protein joined to a trimerization domain. Such vaccines can be used to vaccinate an individual against infection by heterologous influenza viruses and influenza virus that are antigenically divergent from the virus from which the nanoparticle hemagglutinin protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.
    Type: Application
    Filed: March 1, 2013
    Publication date: March 13, 2014
    Inventors: Gary J. NABEL, Masaru KANEKIYO, Chih-Jen WEI, Patrick M. MCTAMNEY, Hadi M. YASSINE, Jeffrey C. BOYINGTON
  • Publication number: 20140058069
    Abstract: The present invention generally relates to particles, including microgel particles, for purifying proteins and other species. In one aspect, the particles comprise a metal-chelating moiety, which may be distributed substantially evenly throughout the particle in certain embodiments. In some cases, the particles may be porous, and in some embodiments, the particles may be made sufficiently small, for example, in order to form a microgel containing the particles. Such particles may be useful, for example, in binding metal ions (for example, nickel ions) using the metal-chelating moieties. In some embodiments, such particles may also be used to bind certain analytes (for example, proteins) containing tags which attract metal ions, for example, histidine tags. Accordingly, in certain embodiments, the particles may be used for binding or trapping proteins.
    Type: Application
    Filed: February 22, 2012
    Publication date: February 27, 2014
    Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Boaz Mizrahi, Daniel S. Kohane
  • Publication number: 20140056820
    Abstract: The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from Neisseria outer membrane proteins, such as Laz. The invention also provides synthetic transit peptides comprised of the pentapeptide AAEAP. The invention further discloses methods for treating cancer, and specifically brain cancer, as well as other brain-related conditions. Further, the invention provides methods of imaging and diagnosing cancer, particular brain cancer.
    Type: Application
    Filed: September 30, 2013
    Publication date: February 27, 2014
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Chang Soo Hong, Tohru Yamada, Arsenio M Fialho
  • Publication number: 20140056810
    Abstract: The present invention relates to bifunctional compounds, the bifunctional compounds for use in molecular imaging and therapy, methods of molecular imaging using the bifunctional compounds and kits including the bifunctional compounds for use molecular imaging. The bifunctional compounds have a tripodal hydroxypyridinone chelating portion and may be conjugated to a targeting group so that the compounds target specific cells or tissues in a subject.
    Type: Application
    Filed: November 11, 2011
    Publication date: February 27, 2014
    Applicant: King's College London
    Inventors: James Russell Ballinger, David Berry, Philip John Blower, Yongmin Ma, Gregory Edgar David Mullen
  • Publication number: 20140051080
    Abstract: Compounds of general formula I are used as labels in an electrochemical assay: (I) in which: Fc and Fc? are substituted or unsubstituted ferrocenyl moieties, X is a C1 to C6 alkylene chain which is optionally interrupted by —O— or —NH—; Y is a C1 to C6 alkylene chain which is optionally interrupted by —O— or —NH—; Z is a C1 to C12 alkylene chain which may optionally be substituted and/or may optionally be interrupted by —O—, —S—, cycloalkyl, —CO—, —CON R1—, —NR1CO— or —NR1— in which R1 represents hydrogen or C1 to C4 alkyl; and R is a linker group. Compounds I are used to make labelled substrates, as well as functionalised compounds for making the labelled substrates.
    Type: Application
    Filed: December 22, 2011
    Publication date: February 20, 2014
    Inventors: Jonathan Sharp, Stephen Flower, Christopher Frost
  • Publication number: 20140051070
    Abstract: The present invention provides a streptavidin-coupled magnetic particle with high biotin-binding capacity, and a manufacturing method thereof. The streptavidin-coupled magnetic particle has a structure in which streptavidins are cross-linked with each other on a magnetic particle. A method for manufacturing the streptavidin-coupled magnetic particle includes the steps of: (1) preparing a suspension containing magnetic particles having amino groups on their surface; and (2) reacting the magnetic particles with streptavidin and glutaraldehyde by adding glutaraldehyde in the presence of streptavidin to the suspension prepared in step (1). The streptavidin-coupled magnetic particle of the present invention, and the streptavidin-coupled magnetic particle manufactured by the manufacturing method of the present invention are useful in clinical diagnosis.
    Type: Application
    Filed: February 15, 2012
    Publication date: February 20, 2014
    Applicant: Kyowa Medex Co., Ltd.
    Inventors: Nobuyuki Arai, Yasuhiro Matsuoka, Kazuki Morita
  • Publication number: 20140051645
    Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) also known as CD152, which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.
    Type: Application
    Filed: December 2, 2011
    Publication date: February 20, 2014
    Inventors: Gabriele Matschiner, Andreas Hohlbaum, Arne Skerra
  • Patent number: 8629239
    Abstract: The present disclosures provides isolated or purified compounds, each of which bind to a metal atom. Generally, the compounds are small in size (e.g, molecular weight of less than about 1 kDa) and peptidic in nature, inasmuch as the compounds comprise amino acids. In some embodiments, the compound comprises a structure of Formula I: M1-P1-M2-P2 wherein each of P1 and P2 is a peptide comprising at least two amino acids, M1 is a first metal binding moiety comprising a substituted imidazolone ring, M2 is a second metal binding moiety comprising a substituted oxazolone ring, and wherein M1 and M2 bind to a single metal atom. Also provided are related complexes, conjugates, cells which synthesize the compounds of the present disclosures, substantially homogenous cultures thereof, kits and compositions, and methods of making or using the materials of the present disclosures.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: January 14, 2014
    Assignees: Iowa State University Research Foundation, Inc., The Regents of the University of Michigan, WiSys Technology Foundation
    Inventors: Jeremy D. Semrau, Warren Gallagher, Sukhwan Yoon, Jeongdae Im, Alan A. DiSpirito, Sung-Woo Lee, Scott Hartsel, Marcus T. McEllistrem
  • Publication number: 20140011983
    Abstract: Methods for targeting a protein by providing an inhibitor covalently linked to a rhodium(II) complex, introducing the inhibitor to the target protein and allowing the inhibitor and protein to interact. The rhodium(II) complex covalently linked to the inhibitor binds the target protein both inorganically and organically and forms stabilizing secondary contacts between the rhodium(II) complex and the protein.
    Type: Application
    Filed: June 12, 2013
    Publication date: January 9, 2014
    Applicant: WILLIAM MARSH RICE UNIVERSITY
    Inventors: Zachary T. Ball, Rituparna Kundu, Brian V. Popp, Dean R. Madden, Patrick R. Cushing
  • Publication number: 20130336947
    Abstract: Disclosed herein are zinc finger peptides having at least 4 zinc finger domains, such as 6, 11, 12 or 18 zinc finger domains. The zinc finger peptides may be fused to effector domains for modulating gene expression. Zinc finger peptides of the invention are useful for targeting trinucleotide-repeat sequences in mutant genes and may have applications in gene therapy. The zinc finger peptides may have nucleic acid recognition sequences according to SEQ ID NO: 101. Also disclosed are methods for constructing poly-zinc finger peptides having arrays of at least 8 zinc finger domains, along with zinc finger frameworks that may be useful for selecting zinc finger peptides from libraries.
    Type: Application
    Filed: October 17, 2011
    Publication date: December 19, 2013
    Applicant: FUNDACIÓ PRIVADA CENTRE DE REGULACIÓ GENÓMICA
    Inventors: Mark Isalan, Mireia Garriga-Canut
  • Patent number: 8609814
    Abstract: The present invention relates to a modified porphyrin-based oxygen-carrying protein, such as haemoglobin, which has been found, in its unmodified state to have a low affinity site of electron transfer and a high affinity electron transfer between a reductant and ferryl haem iron via one or more protein amino acids. The invention provides such proteins that comprise a modification to enhance this pathway.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: December 17, 2013
    Assignee: University of Essex Enterprises Limited
    Inventors: Christopher Eric Cooper, Michael Thomas Wilson, Brandon Jon Reeder
  • Publication number: 20130323274
    Abstract: Variants of the pathogenic E. coli ‘AcfD precursor’ have been identified with increased solubility as compared to the native AcfD protein that raise a substantially similar immune response in a subject as the native AcfD protein.
    Type: Application
    Filed: May 29, 2013
    Publication date: December 5, 2013
    Applicant: NOVARTIS AG
    Inventors: Laura SERINO, Mariagrazia PIZZA, Danilo GOMES MORIEL, Maria Rita FONTANA
  • Publication number: 20130310273
    Abstract: The present inventions relates generally to methods for diagnosing the presence or the risk of development or the therapy control of vasculitis, in particular, of large vessel vasculitis, like giant-cell arteritis (GCA), polymyalgia rheumatica (PMR) and Takayasu's arteritis in a subject, in particular, in mammals. In addition, the present invention relates to test kits for use in the diagnosis of the presence or the risk of development, or for the therapy control of vasculitis, in particular of large vessel vasculitis, like GCA, PMR and Takayasu's arteritis, in a subject.
    Type: Application
    Filed: January 27, 2012
    Publication date: November 21, 2013
    Inventors: Torsten Witte, Niklas Thomas Baerlecken